NasdaqCM:BIOL

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

BIOLASE, Inc., together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. More Details


Snowflake Analysis

Limited growth with imperfect balance sheet.


Similar Companies

Share Price & News

How has BIOLASE's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: BIOL's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

1.2%

BIOL

1.1%

US Medical Equipment

1.0%

US Market


1 Year Return

-70.4%

BIOL

15.4%

US Medical Equipment

13.6%

US Market

Return vs Industry: BIOL underperformed the US Medical Equipment industry which returned 15.4% over the past year.

Return vs Market: BIOL underperformed the US Market which returned 13.6% over the past year.


Shareholder returns

BIOLIndustryMarket
7 Day1.2%1.1%1.0%
30 Day-22.7%1.5%-0.4%
90 Day-38.0%12.0%8.9%
1 Year-70.4%-70.4%16.4%15.4%16.2%13.6%
3 Year-90.0%-90.0%73.3%68.8%40.2%30.8%
5 Year-94.4%-94.4%149.6%130.6%89.6%68.2%

Price Volatility Vs. Market

How volatile is BIOLASE's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is BIOLASE undervalued compared to its fair value and its price relative to the market?

11.73x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate BIOL's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate BIOL's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: BIOL is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.

PE vs Market: BIOL is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate BIOL's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: BIOL is overvalued based on its PB Ratio (11.7x) compared to the US Medical Equipment industry average (3.9x).


Next Steps

Future Growth

How is BIOLASE forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

44.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: BIOL is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: BIOL is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: BIOL is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: BIOL's revenue (43.8% per year) is forecast to grow faster than the US market (9.7% per year).

High Growth Revenue: BIOL's revenue (43.8% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if BIOL's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has BIOLASE performed over the past 5 years?

-0.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: BIOL is currently unprofitable.

Growing Profit Margin: BIOL is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: BIOL is unprofitable, and losses have increased over the past 5 years at a rate of 0.9% per year.

Accelerating Growth: Unable to compare BIOL's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BIOL is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-0.2%).


Return on Equity

High ROE: BIOL has a negative Return on Equity (-1509.55%), as it is currently unprofitable.


Next Steps

Financial Health

How is BIOLASE's financial position?


Financial Position Analysis

Short Term Liabilities: BIOL's short term assets ($22.9M) exceed its short term liabilities ($21.1M).

Long Term Liabilities: BIOL's short term assets ($22.9M) exceed its long term liabilities ($5.4M).


Debt to Equity History and Analysis

Debt Level: BIOL's debt to equity ratio (1274.6%) is considered high.

Reducing Debt: BIOL's debt to equity ratio has increased from 0% to 1274.6% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: BIOL has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: BIOL has less than a year of cash runway if free cash flow continues to grow at historical rates of 3.3% each year.


Next Steps

Dividend

What is BIOLASE current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate BIOL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate BIOL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BIOL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BIOL's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of BIOL's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.0yrs

Average management tenure


CEO

Todd Norbe (53 yo)

2.08yrs

Tenure

US$592,590

Compensation

Mr. Todd A. Norbe is President and Chief Executive Officer at BIOLASE, Inc. since August 7, 2018. He served as President of Dental/Medical Solutions at Sybron Dental Specialties, Inc. Mr. Norbe serves as t ...


CEO Compensation Analysis

Compensation vs Market: Todd's total compensation ($USD592.59K) is about average for companies of similar size in the US market ($USD595.72K).

Compensation vs Earnings: Todd's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Todd Norbe
President2.08yrsUS$592.59k0.44%
$ 125.1k
John Beaver
Executive VP & CFO2.92yrsUS$446.56k0.34%
$ 95.5k
Richard Whipp
Vice President of Operations8.92yrsno datano data
Daniel Merkin
National Sales Directorno dataUS$243.55kno data
Matthew Wilson
Vice President of Human Resources4.33yrsno datano data
Samuel Low
Chief Dental Officer and VP of Dental & Clinical Affairs3.92yrsUS$50.44kno data
Holger Arens
VP & MD of Europe4yrsno datano data
Michael Carroll
Corporate Secretaryno datano datano data
Brendan O'Connell
Vice President of Finance and Corporate Controller5.67yrsno datano data

4.0yrs

Average Tenure

53yo

Average Age

Experienced Management: BIOL's management team is considered experienced (4 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Todd Norbe
President2.08yrsUS$592.59k0.44%
$ 125.1k
Richard Lanman
Independent Director2.92yrsUS$116.50k0.088%
$ 24.7k
Jonathan Lord
Independent Chairman of the Board3yrsUS$249.60k0.42%
$ 116.7k
Michael DiTolla
Independent Director0.83yrUS$6.52kno data
Jess Roper
Independent Director2.25yrsUS$104.17k0.090%
$ 25.4k
Garrett Sato
Independent Director2.42yrsUS$116.50k0.10%
$ 29.3k
Elaine Wagner
Independent Director1.92yrsUS$116.50k0.048%
$ 13.5k

2.3yrs

Average Tenure

59yo

Average Age

Experienced Board: BIOL's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 321.6%.


Top Shareholders

Company Information

BIOLASE, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: BIOLASE, Inc.
  • Ticker: BIOL
  • Exchange: NasdaqCM
  • Founded: 1984
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$28.118m
  • Shares outstanding: 92.19m
  • Website: https://www.biolase.com

Number of Employees


Location

  • BIOLASE, Inc.
  • 4 Cromwell
  • Irvine
  • California
  • 92618
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BIOLNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDMar 1992
BTH1DB (Deutsche Boerse AG)YesCommon StockDEEURMar 1992

Biography

BIOLASE, Inc., together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental lase ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/19 06:17
End of Day Share Price2020/09/18 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.